Search
Vertex Pharmaceuticals Inc
VRTXAdd to Watchlist
547.090USD
+4.590+0.85%
Close 11-06 16:00（ET）
138.67BMarket Cap
32.17P/E TTM
After-hours 16:29 (ET)546.210USD-1.040-0.19%
After-hours 16:29 (ET)Vertex Pharmaceuticals Inc (VRTX) Stock Price Target & Forecast
Analyst Rating
Based on 33 analysts giving stock ratings to Vertex Pharmaceuticals Inc in the past month.
Buy
10 Strong Buy
17 Buy
5 Hold
0 Sell
1 Strong Sell
Target Price
572.009USD+2.35%
VRTX Analyst Recommendation Trends
In the current month, VRTX has received 17 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. VRTX average Analyst price target in the last month is 572.009.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
10
10
9
11
11
11
11
10
17
17
16
17
17
16
17
16
5
5
5
5
5
5
5
6
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
33
33
31
34
34
33
34
33
VRTX Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
Eli Lilly and Co
LLY
10
19
3
1
0
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Merck & Co Inc
MRK
7
16
8
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Regeneron Pharmaceuticals Inc
REGN
6
15
9
0
0
30
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Financial Forecasting
Based on analysts' estimates, VRTX EPS is projected to reach 4.139 in FY2026Q4, following reported EPS of 2.578 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
4.31
4.74
4.79
4.14
4.70
Actual
4.06
4.34
2.58
--
--
Surprise
-5.90%
-8.49%
-46.14%
--
--
FAQs
What is Vertex Pharmaceuticals Inc's expected revenue for the next quarter?
Vertex Pharmaceuticals Inc's expected revenue is 3.52B.
What is Vertex Pharmaceuticals Inc's price target?
Analysts forecast that Vertex Pharmaceuticals Inc's price target is USD 590.66, with the highest forecast at USD 725.00 and the lowest forecast at USD 350.00.
How have Vertex Pharmaceuticals IncVRTX's recent earnings per share performed?
The market expectation was USD 2.58, while Vertex Pharmaceuticals IncVRTX's earnings per share (EPS) for the previous quarter was USD 4.34. EPS for the next quarter is expected at USD 4.14.
What is the analyst rating for Vertex Pharmaceuticals Inc?
Based on the ratings of Vertex Pharmaceuticals Inc's stock from 33 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.